AMENDMENTS TO CLAIMS

Claim 1. (Cancelled).

Claims 2 and 3. (Cancelled).

Claim 4. (Cancelled).

Claim 5. (Currently Amended) A pharmaceutical composition comprising a core in the form of a beadlet and an enteric coating for said core, said core comprising about 80% to about 100% by weight of an acid labile medicament which is 2′,3′-dideoxyinosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, potassium alginate, sodium alginate and partially pregelatinized corn starch, said composition being devoid of a protective coat or subcoat between the core and the enteric coating, wherein the weight ratio of enteric coating to core is between about 0.0:5:1 to about 0.6:1, and wherein the enteric coating should provide protection of the medicament at a pH less than 3 but will permit drug release at a pH of 4.5 or higher, said enteric coating comprising a polymer which is selected from the group consisting of polyvinyl acetate phthalate, cellulose acetate phthalate and a methacrylic acid copolymer.

Claims 6 and 7. (Cancelled).

Claim 8. (Original) The pharmaceutical composition of Claim 5 wherein said enteric coating comprises a polymer and a plasticizer.

Claim 9. (Previously Presented) The pharmaceutical composition of Claim 8 wherein said polymer is selected from the group consisting of polyvinyl acetate phthalate and cellulose acetate phthalate.

Claim 10. (Previously Presented) The pharmaceutical composition of Claim 8 wherein said polymer comprises a methacrylic acid copolymer.

Claim 11. (Original) The pharmaceutical composition of Claim 10 wherein said enteric coating includes the methacrylic acid copolymer in an amount within the range of from about 5 to about 30% of the total composition weight, and said plasticizer in an amount within the range from about 0.5 to about 6% of the total composition weight.

Claim 12. (Previously Presented) The pharmaceutical composition of Claim 10 wherein said methacrylic acid copolymer is a copolymer of methacrylic acid and ethyl acrylate.

Claim 13. (Original) The pharmaceutical composition of Claim 8 wherein said plasticizer is triethyl citrate, triacetin, tributyl sebecate, or polyethylene glycol.

Claim 14. (Original) The pharmaceutical composition of Claim 8 wherein said plasticizer is diethyl phthalate.

Claim 15. (Previously Presented) The pharmaceutical composition of Claim 8 wherein said enteric coating includes methacrylic acid copolymer and diethyl phthalate.

Claim 16. (Original) The pharmaceutical composition of Claim 5, further comprising an anti-adherent coating disposed on the exterior of said enteric coating.

Claim 17. (Cancelled)

Claim 18. (Previously Presented) The pharmaceutical composition of Claim 16 wherein the anti-adherent coating is magnesium stearate or fumed silica or talc.

Claim 19. (Cancelled)

Claim 20. (Original) The pharmaceutical composition of Claim 16 wherein said anti-adherent is present in an amount within the range from about 0.1% to about 4.0% of the total composition weight.

Claim 21. (Previously Presented) The pharmaceutical composition of Claim 5 wherein said disintegrant is cross-linked sodium carboxymethylcellulose, corn starch, or cross linked polyvinylpyrrolidone.

Claim 22. (Original) The pharmaceutical composition of Claim 5 wherein said disintegrant is sodium starch glycolate.

Claim 23. (Original) The pharmaceutical composition of Claim 5 wherein said binder is alkaline.

Claim 24. (Previously Presented) The pharmaceutical composition of Claim 23 wherein said binder is sodium carboxymethylcellulose.

Claims 25 and 26. (Cancelled).

Claim 27. (Currently Amended) A pharmaceutical composition comprising a core in the form of a beadlet and an enteric coating for said core, wherein said core comprises about 95% by weight 2′,3′-dideoxyinosine, about 1% by weight sodium carboxymethylcellulose and about 4% by weight sodium starch glycolate, and said enteric coating comprising a copolymer of methacrylic acid and ethyl acrylate.

Claim 28. (Previously Presented) The pharmaceutical composition of Claim 5 wherein said composition is encapsulated in a capsule for oral administration.

Claim 29. (Previously Presented) The pharmaceutical composition of Claim 28 wherein said capsule is filled with said composition in an amount equivalent to attain a dosage of 2′,3′-dideoxyinosine required for twice daily administration.

Claim 30. (Previously Presented) The pharmaceutical composition of Claim 28 wherein said capsule is filled with said composition in an amount equivalent to attain a dosage of 2′,3′-dideoxyinosine required for once daily administration.

Claim 31. (Original) A pharmaceutical composition comprising:

a) a dissolvable capsule; and

b) the pharmaceutical composition of Claims 5, 16, or 27 which is encapsulated within said dissolvable capsule.

Claims 32 to 53. (Cancelled).

Claim 54. (Previously Presented) The pharmaceutical composition of Claim 5 wherein the enteric coating includes an alkalizing agent.

Claim 55. (Previously Presented) The pharmaceutical composition of Claim 27 wherein the enteric coating includes an alkalizing agent.